Currently, there are over 100 Covid-19 clinical trials expected to begin in 2022 and 2023, with 93% expected in 2022. When looking at the top sponsors, Novavax is expected to start the most Covid-19 clinical trials in the future with seven trials. A breakdown of their trials by phase can be seen below.
Novavax will be initiating all its Covid-19 trials in 2022, with the most recent ones expected to begin on 31 March. These two Phase IV trials will be testing the company’s Covid-19 vaccine Covovax (Nuvaxovid). The intramuscular vaccine consists of a recombinant spike protein of the SARS-CoV-2 virus acting as an immunising agent with the matrix-M adjuvant. An adjuvant is an active ingredient in vaccines that creates a stronger immune response and is easier to store, as it only needs to be kept at refrigerator temperature. Results from the 15,000-patient Phase III clinical trial showed positive efficacy and safety. Currently, this vaccine is not yet approved in the US, but Novavax expects to file a biologics license application (BLA) in the second half of 2022.
The other trials Novavax plans to initiate include three other Phase IV trials, all expected to begin in the first half of 2022, and a Phase III paediatric trial, “Pediatric Study of Coronavirus Disease 2019 (Covid-19) vaccine in Younger Children.” This is an interventional study of its Covid-19 vaccine in younger children that is expected to begin in June 2022.
Last is a Phase II trial, “Phase II Study of Covid-NanoFlu Combination Vaccine and NanoFlu Standalone,” which will test its ICC vaccine with its NanoFlu, and also its NanoFlu alone. NanoFlu is currently being tested for the treatment of influenza. Both trials are expected to begin in December 2022.
Although Johnson & Johnson’s single-dose vaccine is an mRNA alternative that competed against Moderna and Pfizer, it fell short with adverse side effects. Novavax looks to push its own mRNA alternative that uses older vaccine technology to market, to provide an extra vaccine choice during the ongoing pandemic.